Targeted Triplet Induction Regimens in Acute Myeloid Leukemia
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Gail Roboz, MD, Weill Cornell Medicine, New York, New York, discusses emerging strategies in acute myeloid leukemia (AML) treatment.
Dr Roboz highlights the growing role of triplet regimens built on a hypomethylating agent and venetoclax backbone, emphasizing the addition of targeted therapies such as IDH, FLT3, and menin inhibitors, as well as a potential shift away from intensive chemotherapy, including 7 plus 3, across both older and younger patient populations.
Transcript:
Hi, my name is Gail Roboz, I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and New York-Presbyterian Hospital.
I had the fun task of talking about triplets in AML therapy, with the goal of presenting new data on what can be added to hypomethylating agents and venetoclax to make treatment of AML better.
I think this is the hot, exciting space in AML currently because we know that we might be able to move away from intensive chemotherapy, move away from 7 plus 3 in a lot of patients. So it isn't actually only older and more frail patients who are going to be getting hypomethylating agents and venetoclax, lots of young patients are going to be on that regimen too and we've been discussing what can be added on to [hypomethylating agent] and venetoclax to make it better—IDH inhibitors, FLT3 inhibitors, menin inhibitors.
I think this is the hot current space, and you're going to see more and more data on younger patients and older patients alike benefiting from the addition of targeted agents to a hypomethylating agent and venetoclax backbone.
Source:
Roboz G. Updates in targeted triplet induction regimens in AML for 2026 practice. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30 - February 1, 2026. Amelia Island, Florida.
